Russian prime minister declares 3rd Winter World Military Games openMilitary & Defense February 24, 22:33
Russia to veto UNSC resolution imposing sanctions on Syria — envoyRussian Politics & Diplomacy February 24, 22:29
Ukrainian MP Savchenko arrives in Donetsk republic to visit Ukrainian prisoners — agencyWorld February 24, 22:25
Russian Defense Ministry surprised over German MPs reaction to Reichstag miniature plansRussian Politics & Diplomacy February 24, 16:32
Iraq's PM orders airstrikes on IS positions in SyriaWorld February 24, 16:09
Nord Stream 2 financing model to be ready by year end - OMVBusiness & Economy February 24, 13:44
Churkin left bright mark in history of Russian diplomacy, Lavrov saysRussian Politics & Diplomacy February 24, 12:20
Cargo spacecraft docks ISS in automatic modeScience & Space February 24, 11:58
Belarus to present to European Commission report on NPP stress tests' results - ministryBusiness & Economy February 24, 11:36
HAYWARD, Calif., April 19, 2012 /PRNewswire/ -- Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and a global market leader in aesthetic treatments, today announced the results of a first-of-its-kind, IRB-approved clinical study that evaluated the use of its novel 1440nm fractional laser to assess the effect of this treatment on the appearance of pores, skin texture and overall appearance of skin.
The study utilized Solta's newest fractional resurfacing platform, the Clear + Brilliant™ Laser System, which is used by clinicians worldwide to help patients prevent the initial signs of photo-aging, maintain the look and feel of their youthful appearance, and improve the texture and tone of aging and sun-damaged skin. The complete research findings will be presented at the 32nd American Society for Laser Medicine and Surgery (ASLMS) Annual Conference in Kissimmee, Fla. on April 18 through April 22, 2012.
The clinical study is the first to objectively measure the effects of a fractional device on facial pores. It included 20 patients (Fitzpatrick I-IV) who received six treatments spaced two weeks apart. Each patient received a full-face treatment consisting of eight passes at the highest tolerable energy level. A photographic assessment of facial pores using the VISIA-CR Imaging system was performed before treatment at each visit and subjective measurements were recorded by both the subject and investigator regarding pore appearance, appearance of skin texture, and overall skin appearance. After a series of six treatments, there was a significant reduction in pore score (p<0.002) and investigators and subjects noted moderate-to-marked improvement in pore appearance, including pore count and size. Ninety-five percent of all patients treated reported visible improvement in pore appearance, with 60 percent reporting at least moderate-marked improvement. In addition, 100 percent of patients reported improvement in skin texture and overall appearance, with 90 percent reporting at least moderate-marked improvement. The treatment was well tolerated with some mild-moderate erythema and less-than-mild edema and there were no long term side effects and no serious adverse effects reported.
"This research is exciting since pore size has never been systematically studied before and it is such an area of concern for patients," said clinical investigator Jeffrey S. Dover, M.D., Associate Clinical Professor of Dermatology, at Yale University School of Medicine, and co-founder of SkinCare Physicians, in Chestnut Hill, Mass. "The results demonstrate that Clear + Brilliant can improve not only the tone and texture of the skin, but also can significantly reduce both pore count and pore size in all skin types."
Dr. Dover and Dr. Nazanin Saedi will be presenting these findings at ASLMS on Saturday, April 21st during the Cutaneous Laser Surgery Session from 3:45-3:51 p.m. in Florida Hall D (reference page 80).
"Solta Medical is pleased with the results of this study and the potential Clear + Brilliant has for addressing an important aesthetic patient need," said Stephen J. Fanning, Chairman of the Board, president and CEO of Solta Medical, Inc. "Support for this study is part of Solta's ongoing commitment to the aesthetic medical community to provide clinicians with the data they need to make informed choices on behalf of their patients."
For more information on Solta Medical, please visit www.Solta.com and Solta Medical (booth # 708).
About SOLTA MEDICAL, INC.
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers six aesthetic energy devices to address a range of issues, including skin resurfacing and rejuvenation with Fraxel® and Clear + Brilliant™, body contouring and skin tightening with Liposonix® and Thermage® and acne reduction with Isolaz® and CLARO™. As the innovator and leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Using the same fractional laser technology, Clear + Brilliant is a unique, cost-effective treatment to correct and prevent early signs of aging. For body contouring, Liposonix is a non-surgical treatment to reduce waist circumference with advanced high-intensity focused ultrasound (HIFU) technology to permanently destroy targeted fat beneath the skin. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. Isolaz was the first laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the first FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. More than two million procedures have been performed with Solta Medical's portfolio of products around the world.
For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.
© 2012 Solta Medical, Inc. All rights reserved. Thermage, Fraxel, Isolaz, Clear + Brilliant, CLARO, Liposonix and Solta Medical are trademarks or registered trademarks of Solta Medical, Inc. or its subsidiaries.
Solta Medical, Inc.
Jennifer Hacker, COHN & WOLFE